LONDON, October 7, 2015 /PRNewswire/ --
Contracted drug production - stay ahead now by exploring leading companies' prospects
How are pharma contract manufacturing organisations (CMOs) performing? Visiongain's updated report shows you their prospects to 2025. You discover that outsourcing industry's results, trends, opportunities and potentials, also with predicted revenues and profits.
Our study analyses 30 top CMOs. There you see how revenues from drug production services can increase. You explore trends, technologies and opportunities shaping that industry. Discover that market's potential, benefiting your reputation for commercial insight.
That way you find analysis on established and emerging companies across the world. Read on, please, to scan the leading companies and see revenue prediction for their industry.
Forecasts and other data to help you stay ahead, benefiting your influence
In our new study you find analytical profiles of 30 top contractors, and analyses of their overall industry. You discover historical data, market and sales shares, growth rates and revenue forecasts. Also explore qualitative analyses, business outlooks and developments.
Our study gives you 185 tables, 111 charts and three interviews with companies.
That investigation also shows you prospects for these outsourced production segments at world level, including their overall revenue forecasts to 2025:
• Active pharmaceutical ingredients (API) production
• Finished dosage formulations (FDF) manufacturing.
In particular, biologics and biosimilars hold promise. New therapies - including antibody-drug conjugates, high potency APIs and regenerative medicines - increasingly interest CMOs and clients.
Discover, then, what the future holds. The following sections highlight what our research and analyses give you, to benefit planning, proposals and presentations.
Company profiles - explore commercial activities, results, competition and prospects
Our report analyses 30 leading companies. The content of each profile differs, depending on the organisation. In general, though, a profile gives you the following information:
• Overview of the company's contract manufacturing services and operations
• Analysis of recent financial performance - annual revenue for CMO services, including some data on operating profit and margins
• Assessment of developments - activities, acquisitions, production capacity, deals, new service offerings and collaborations
• SWOT analysis - a firm's strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth from 2015 onwards
• Forecasting of pharmaceutical manufacturing revenue to 2025 (for 26 firms), as well as projected operating profit and margin for some companies.
Pharmaceutical developers, producers and marketers will increasingly use CMOs. With our study you discover what that industry's participants offer - along with their trends and revenue potentials - helping you stay ahead in knowledge and benefit your authority
European contract manufacturing organisations
Our study gives you discussions, financial analyses and commercial outlooks for 14 European CMOs, including these firms:
• Lonza
• Evonik Degussa
• Royal DSM
• Boehringer Ingelheim
• Fareva
• Famar
• Vetter Pharma.
Discover what the future holds for those pharma service providers, including revenue outlooks to 2025. What profitability and other achievements are possible?
CMOs based in the US and Japan
Our report also shows you developments and business outlooks for seven other international drug production contractors:
• Catalent Pharma Solutions
• Patheon
• Baxter BioPharma Solutions
• AbbVie Contract Manufacturing
• Pfizer CentreSource
• Daito Pharmaceutical
• Nipro Corporation.
Our work reveals where sales growth can occur. Many opportunities remain, with high, expanding revenues forecasted from 2015. You discover where prospects for sales expansion exist, seeing what is possible for that business and its leading competitors.
Developed-market API specialists
You also discover outlooks for three top producers of active pharmaceutical ingredients:
• Teva API
• Esteve Química
• Euticals.
Our report shows commercial potentials of that industry. You see possibilities for advancing medical technology and raising business performance, with better serving of clients.
India and China - analysis of pharma manufacturing service providers
Our work assesses six Indian and Chinese companies. You discover activities and prospects of these firms:
• Dr. Reddy's Laboratories
• Aurobindo Pharma
• Divis Laboratories
• Shandong Xinhua Pharmaceutical
• Zhejiang Hisun Pharmaceutical
• Zhejiang Huahai Pharmaceuticals.
That way you find sales data and underlying trends, exploring what the present and future hold.
Predictions for the worldwide pharma CMO market and submarkets
Our report also forecasts revenues to 2025 for the world contract manufacturing industry and its main segments: APIs and FDFs.
That work predicts high sales growth from 2015 to 2025. Revenues can reach $80.5bn in 2019, with further expansion possible. We predict large companies and specialty healthcare firms will develop and prosper. She why, how and where, finding commercial potentials.
You also discover interviews with authorities in these three companies, hearing how firms think and view prospects for outsourced drug production:
• Corden Pharma
• Siegfried
• PREMAS Biotech.
With our study you explore opportunities and sales predictions for outsourced production of medicines. You investigate established and rising companies, finding trends, outlooks and revenue potentials. See what is possible.
Ways Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) - Market, Industry, Trends, Technologies and Prospects 2015-2025 helps your work
In particular, our new investigation benefits your research, planning and decisions through the following analyses:
• Revenues to 2025 for the world pharma contract manufacturing organisations (CMO) market - discover that industry's prospects overall and by submarket, finding promising segments for investments, developments and revenue growth
• Profiles of 30 leading companies there - assess services, strategies, sales results and outlooks, gaining revenue forecasts to 2025 for 26 of the firms, also with some profitability predictions
• Interviews with three companies in the CMO industry - explore strategies, debates and opinions, helping you stay ahead in knowledge
• Competition and opportunities - see what affects that industry, exploring what shapes its future, esp. prospects for sustaining and developing business
• Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and succeed.
That report, by visiongain's in-house analysts in the UK, gives analysis with the purpose of saving you effort and time. You gain data and discussions leading companies depend on.
Information there found nowhere else, helping you research, analyse and plan
Our survey gives independent analysis. There you gain competitive intelligence found only in our report, exploring leading CMOs and their potentials.
By choosing our study you are less likely to fall behind in knowledge or miss opportunity. Discover there how you could benefit your research, analyses and decisions. Also see how you could save time and gain in recognition for technological and commercial insight.
Prospects for pharma manufacturing service providers - try our new analysis now
Our new investigation gives you data, trends and business predictions for outsourced drug and API production. Avoid missing out - instead please get our report here now.
To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100
Or click on https://www.visiongain.com/Report/1509/Pharma-Leader-Series-Top-30-Pharmaceutical-Contract-Manufacturing-Organisations-(CMOs)-Market-Industry-Trends-Technologies-and-Prospects-2015-2025
Companies Listed
Abbott Laboratories
Abic
AbbVie
Actavis
Adamas Pharmaceuticals
Aegerion
Aenova Group
Aesica Pharmaceuticals
Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM)
Agência Nacional de Vigilância Sanitária (ANVISA)
Agennix
Aguettant
AlgoNomics
Alliance Medical Products
Almac Group
Alpharma
Amgen
AMYRA Biotech
Andeno
Apexigen
Aptuit
Archimica
Arecor
ArGEN-X
Astellas
AstraZeneca
Athera Biotechnologies
Aurobindo Pharma
Avalanche Biotechnologies
Banner Life Sciences
BaroFold
Barr-Pliva
BASF
Baxter BioPharma Solutions
Bayer
BC Partners
Becton and Dickinson (BD)
Beijing Double-Crane Pharmaceutical
Bentley
Biocraft
Biogal
Biomedical Advanced Research and Development Authority (BARDA)
Bionomics
Biotest
BioWa
Boehringer Ingelheim
Bridgepoint Capital
Bristol-Myers Squibb
Britest
Canyon
Carbogen Amcis
Cardinal Health
Catalent
Celladon
Celldex Therapeutics
Celsion
CEVEC Pharmaceuticals
Chemtrix BV
China National Pharmaceutical Group (SInopharm)
Chirotech
Circadian Technologies
Cleveland BioLabs
Cobra Biomanufacturing
Companies House
CordenPharma
Corvette Pharmaceutical Services
Daiichi Sankyo
Daito
DecImmune Therapeutics
Delmas Perfusion
Delpharm
Divis Laboratories
DPx Holdings
Dr. Reddy's Laboratories
Dragenopharm Apotheker Püschl and Swiss Caps
Eclipse Therapeutics
Eindhoven University of Technology
Eisai
Eli Lilly
EmulTech
Esteve Química
Euro Vital Pharma
European Medicines Agency (EMA)
Euticals
Evonik Degussa
Excella
Exelixis
Famar
Fareva
Farmaprojects
Frazier Healthcare
Fuyang Xinghai Investment
Genentech
Générique Même Médicament (GEMME)
Genzyme
GSK
Corixa
Haupt Pharma
Health Canada
Hejiang Jiang Yuan Tang Biotechnology
Human Genome Sciences
ICI
Immune Pharmaceuticals
Immunomedics
Index Ventures
Indoco Remedies
Intellect Neurosciences
International Chemical Investors Group
Ivax API
Japanese Ministry of Health Labor and Welfare (MHWL)
Japanese Pharmaceutical and Medical Devices Agency (PMDA)
JK Pharmaceutical
JLL Partners
Johnson & Johnson (J&J)
Kadmon
Laboratoires Besins
Lanxess Corporation
LBO Italia Investimenti s.r.l
Lonza
Marinopoulos Group.
MedImmune
Merck KGaA
Merck Serono
Mesoblast
Molecular Partners
Moody's Corporation
Mylan
NIH CRM
Nipro Corporation
Novartis
Novasep
Novozymes
NPS
OctoPlus
OncoMed Pharmaceuticals
Opthea
Osiris Therapeutics
Otsuka Pharmaceutical
Pantec
Patheon
Perrigo
PFC
Pfizer
Pharmacia
Pharmacyclis
Pharmintraco
Piramal
Plantex
Poli Industria Chimica
Progenics Pharmaceuticals
Prosintex
R5 Pharmaceuticals
RAG AG
Ranbaxy Labs
Recipharm
Regeneus
Relthy Laboratórios
Relypsa
Respirics
Rexim
Roche
Royal DSM
Sandoz
Sanofi
Sanquin Blood Supply foundation
Sanwa Kagaku Kenkyusho
Schering
ScinoPharm
Seattle Genetics
Sentry BioPharma Services
Servier
Shandong Tianda Biological Pharmaceutica
Shandong Xinhua Pharmaceutical
Shanghai Pharmaceutical
ShangPharma
Shire
Sicor
Siegfried
Sigmar Italia
Silverfleet Capital
Sinochem
SkyePharma
Solvay
Sun Pharma
Supernus Pharmaceuticals
SurModics
Swedbank
Swedish Orphan Biovitrium AB (Sobi)
Synkem
Syntex
Synthon
Takeda
Temmler Group
Tessenderlo Group
Teva Pharmaceutical Industries
Theramax
Tianjin Tianyo Pharmaceuticals
Tianma Tianji
Tunitas Therapeutics
UCB
UK Health and Safety Executive
UK Medicines and Healthcare Products Regulatory Agency (MHRA)
UMN Pharma
UniQure
University College London (UCL)
University of Bradford
University of Durham
University of Leeds
US Food and Drug Administration (FDA)
Vetter Pharma
Vidara
ViroPharma
Vivante GMP Solutions
VTU Technology
West Pharma
Wockhardt
XOMA
Yiwu Huayi Investment
Zhangjiang Biotech & Pharmaceutical Base Company
Zhejiang Hisun Pharmaceutical
Zhejiang Huahai Pharmaceuticals
To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44(0)20-7336-6100
SOURCE Visiongain
